Prognostic Significance of the CD10+CD19+CD34+B-Progenitor Immunophenotype in Children with Acute Lymphoblastic Leukemia: A Report from the Children's Cancer Group

Publisher Website
Google Scholar
Abstract
Leukemic cells from most patients with B-lineage acute lymphoblastic leukemia (ALL) appear to originate from normal B-lymphocyte precursors. The earliest B-cell progenitors co-express the antigens CD10, CD19, or CD34 on their cell surfaces. In a large cohort of 2028 children with ALL, we compared treatment outcomes of a subset of B-lineage ALL patients with CD10+CD19+CD34+ immature B-progenitor leukemia (BPL) to the treatment outcomes of the remaining CD19+ B-lineage ALL patients. Pediatric B-lineage ALL cases enrolled on risk-adjusted ALL treatment protocols of the Children's Cancer Group were immunopheno-typically classified as BPL or non-BPL. Patients were stratified further into age groups of ≥1 year and +CD19+CD34+ immature B-progenitor immunophenotype is associated with favorable characteristics for children with ALL and identifies a subset of infants who achieve favorable EFS outcomes.